# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Matthew Biegler reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and raises the price target ...
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $28 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $23 price...
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0....
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $28 price target.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and raises the price ta...
- SEC Filing
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.8% on Friday. The Dow traded u...